Senores Pharmaceuticals is into Healthcare & Pharmaceuticals Pharmaceutical sector and is looking raise funds through Fresh Issue and Offer For Sale
IPO Summary
Senores Pharmaceuticals IPO is a public offering of shares by Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot. The IPO will open on December 20 and will close on December 24. The price band is ₹372 to ₹391 per share and the lot size is 38 shares. The issue size is ₹582.11 crore. The shares are expected to be listed on NSE, BSE on December 30 (^). Some additional information that you may find useful are: 60.9%/32.4%/1.5%/3.4%/1.8% of the revenue during 6MFY25 comes from Regulated markets/Emerging Markets/Critical care injectable business/API business/Others (v/s 67.7%/20.6%/2.7%/6.5%/2.6% in FY24): (**) - based on higher price band (^) indicative datePromoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot Currently promoters hold 66.67% stake in the company. While post-equity promoters stake will be 45.76%
- Company aims to raise between Rs 578 to 582 crs through this IPO.
- The net proceeds of the issue will be utilized to 1) Investment in subsidiary towards a) Rs107 cr capex b) Rs20.2 cr debt repayment/pre-payment 2) Rs73.4 cr towards debt repayment/pre-payment 3) Rs43.2 cr towards working capital of the company 4) Rs59.4 cr Investment in other subsidiary companies towards working capital 5) Funding inorganic growth opportunities and general corporate purpose
- Anchor bidding is expected to commence one day prior to the IPO dates. Tentative anchor bidding date would be 19-Dec-24.
- Price band for the IPO has been fixed at Rs 372 to 391 per share and bid lot are in multiple of 38 shares. The implied market cap post-issue at Rs 1,737 to 1,801 crs.
- As per the tentative schedule, allotment date of this IPO is most likely on December 26 and share are expected to be listed on NSE, BSE on December 30.
- Company has direct peer competition in India'a Pharmaceutical Manufacturing Industry. In Listed space peers include Ajanta Pharma, Alembic Pharma, Caplin Point Lab, Gland Pharma, Strides Pharma among others.
- Equirus Capital, Ambit has been appointed as Merchant Banker to the issue. Link Intime India Pvt. Ltd. has been appointed as official registrar of the issue.
- Company has not undertaken Pre-IPO placement.
Key Pointers of Senores Pharmaceuticals IPO:
| Senores Pharmaceuticals Limited IPO Snapshot | UdhyamPitch on X | |||
|---|---|---|---|
| Established | City | Sector | Sub-Sector |
| 2017 | Ahmedabad | Healthcare & Pharmaceuticals | Pharmaceutical |
| Issue | Issue Type | Tentative Listing Date | Listing at |
| IPO (Fresh+OFS) | Book Building | 30-Dec-24 | NSE, BSE |
| IPO Dates | Price Band (Rs/sh) | Face Value (Rs/sh) | Min Lot Qty |
| 20-Dec-24 to 24-Dec-24 | ₹ 372 to 391 per sh | ₹ 10 per sh | 38 sh and in multiples |
| Retail App (min) | Retail App (max) | Non-Retail (Rs2-10L App) | Non-Retail (>Rs10L min App) |
| 38 shares ₹ 14,858 | 494 shares up to ₹ 193,154 | 532 to 2,546 shares ₹ 208,012 to 995,486 | 2,584 shares and above ₹ 1,010,344 and above |
There are highly chances of variation in data. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
About Senores Pharmaceuticals Limited
Established in 2017, Senores Pharma is research driven pharmaceutical company engaged in developing and manufacturing generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. Company received approvals for 19 ANDAs as on FY24. Company has presence into 43 countries. It also operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.
60.9%/32.4%/1.5%/3.4%/1.8% of the revenue during 6MFY25 comes from Regulated markets/Emerging Markets/Critical care injectable business/API business/Others (v/s 67.7%/20.6%/2.7%/6.5%/2.6% in FY24)
About Industry
As per the F&S Report, the US pharmaceutical market increased from USD 589.0 billion in CY 2021 to USD 711.0 billion in CY 2023. The US CDMO market grew from USD 36.3 billion in CY 2021 to USD 44.7 billion in CY 2023. The Emerging pharmaceutical market rose from USD 354.3 billion in CY 2021 to USD 376.3 billion in CY 2023. The Indian hospital channel market expanded from USD 3.9-4.7 billion in CY 2021 to USD 4.7-5.7 billion in CY 2023 while the India API market increased from USD 11.5 billion to USD 13.1 billion in the same period.
| Senores Pharmaceuticals Limited IPO Dates | UdhyamPitch on X | |
|---|---|
| Anchor Open | 19-Dec-24 |
| IPO Open | 20-Dec-24 |
| IPO Close | 24-Dec-24 |
| Allotment | 26-Dec-24 |
| Credit of Shares | 27-Dec-24 |
| Refund | 27-Dec-24 |
| Listing | 30-Dec-24 |
| Anchor Investor Lockin (50% of Anchor book investment) | |
| Anchor Investor Lockin (Balance 50% of Anchor book investment) | |
Kindly note UPI Mandate deadline is 5:00 pm IST on closing date. To avoid last minute issue, request you to approve UPI mandate before 4:00 pm IST on last day. In case, UPI mandate has not been approved during the prescribed time period, applications are liable to get rejected.
There are highly chances of variation in dates. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
| Senores Pharmaceuticals Limited IPO - Management Details: | |
|---|---|
| Swapnil Jatinbhai Shah, Managing Director | |
| Sanjay Shaileshbhai Majmudar
, Chairman and Non Executive , Non-Independent Director | |
| Deval Shah, Whole time Director and Chief Financial Officer | |
| Nidhi Dilipbhai Kapadia, Company Secretary and Compliance Officer | |
Visit DRHP / RHP for more details on Board of Directors and Management details.
| Senores Pharmaceuticals Limited IPO - Details of Offer/Issue Breakup | UdhyamPitch on X | |||||
|---|---|---|---|---|---|
| Category | Quota (%) | No of Shares-Lower | No of Shares-Upper | Value (Rs Cr)-Lower | Value (Rs Cr)-Upper |
| QIB (Incl Anchor) | 75 | NA | 11,109,543 | NA | 434.38 |
| Non-Retail (NII) | 15 | NA | 2,221,909 | NA | 86.88 |
| Non-Retail (NII): >Rs10L | NA | 1,481,273 | NA | 57.92 | |
| Non-Retail (NII): Rs2L-Rs10L | NA | 740,636 | NA | 28.96 | |
| Retail | 10 | NA | 1,481,272 | NA | 57.92 |
| Employee | NA | 75,000 | . | . | |
| Shareholder | NA | 75,000. | . | ||
| NA=Not Available or Not Calculated | Upper= Upper Price Band | Lower=Lower Price Band | |||||
There are highly chances of variation in data. Users are requested to visit BSE, NSE, SEBI to gather information or read DRHP / RHP for more information.
Check IPO Allotment status of Senores PharmaceuticalsIPO:
| Senores Pharmaceuticals Limited - Anchor Lockin Dates and Details | |
|---|---|
| Anchor Investor Lockin (50% of Investment for 30 days) release of | |
| Anchor Investor Lockin (Balance Investment for 90 days) release of | |
Above information is automatically calculated based on estimations. Chances of errors/changes could be possible due to holidays and/or other conditions. Users are requested to Visit BSE, NSE, SEBI for more information or contact the Company/Merchant Banker/RTA for more information.
| Senores Pharmaceuticals Limited - Documents | |
|---|---|
Disclaimer:
Above article only publishes details on the companies and about forthcoming / upcoming IPO' and are solely intended for educational purpose. We don't solicit or invite any interest of user to invest in any of the investment products. Please review DRHP/RHP/Prospectus for more details about the company, fundamentals and other details. Please visit respective sources to verify and know more details about the IPO. SME IPOs can be more volatile due to smaller market capitalization and liquidity. Prices may fluctuate significantly in response to market conditions. We advise users and/or investors to take opinion from certified and SEBI registered experts before taking any investment decisions.
| Source: SEBI, BSE, NSE |
|---|
FAQ
Posts
0 Comments